The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 30, 2020

Filed:

May. 19, 2016
Applicants:

National Center of Neurology and Psychiatry, Tokyo, JP;

Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;

Inventors:

Takashi Yamamura, Tokyo, JP;

Masakazu Nakamura, Tokyo, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); G01N 33/53 (2006.01); G01N 15/14 (2006.01); G01N 33/48 (2006.01); A61K 45/00 (2006.01); A61P 25/00 (2006.01); C07K 16/28 (2006.01); G01N 15/00 (2006.01);
U.S. Cl.
CPC ...
G01N 15/14 (2013.01); A61K 39/395 (2013.01); A61K 45/00 (2013.01); A61P 25/00 (2018.01); C07K 16/2866 (2013.01); G01N 33/48 (2013.01); G01N 2015/008 (2013.01); G01N 2800/285 (2013.01); G01N 2800/52 (2013.01);
Abstract

According to the present invention, the therapeutic effect of an IL-6 inhibitor on MS was found to be predictable by using as indicators the amount of plasmablasts and/or the indicator of change in immature plasmablasts (amount of immature plasmablasts or amount of follicular helper T cells) in MS patients with a large amount of plasmablasts. Furthermore, IL-6 inhibitors were found to be effective against MS in which plasmablasts occur at high levels and in which the indicator of change in immature plasmablasts is high. The present invention provides methods for selecting MS cases for which treatment with an IL-6 inhibitor is effective, and also provides an effective therapeutic method for patients with MS in which plasmablast occur at high levels and in which the indicator of change in immature plasmablasts is high.


Find Patent Forward Citations

Loading…